IndustryCompany release

20/20 BioLabs Q3 revenue slips to $0.38M; Vermont firefighter cancer screening contract signed

🇺🇸 20/20 Biolabs, Inc. (AIDX) · Mon 16 Nov 2026

The US diagnostics company reported a third-quarter net loss of $1.38M, while a two-year Vermont screening deal is expected to add revenue in the fourth quarter.

20/20 BioLabs reported results for the quarter ended 30 September 2026 in a release dated 16 November. Third-quarter revenue was $0.38M, down from $0.42M in the same period a year earlier, and the company recorded a net loss of $1.38M.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): 20/20 Biolabs, Inc. ↗

Article written by VigiEye from the official source (20/20 Biolabs, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →